Bryan Garnier - ASTROCAST SA (ASTRO) Dropping Coverage

Report

Bryan Garnier

Thomas Coudry

Dropping Coverage

From 15th September 2023, we will no longer include Astrocast in our research universe

15/09/2023 1 EN

Underlying

ASTROCAST SA

See profile

CH1122548808 Oslo Bors Switzerland

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Thomas Coudry

Other Reports on these Companies

On the shelves now: Consumer weekly #42

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the resolution of the ILA port strike which threatened the US holiday sho

12h / 36m 12h / 36m 1 EN

Bruno Bulic

Bruno Bulic

Abivax: Obefazimod in Crohn's disease clinical development

Abivax announced the start of clinical investigations in Crohn’s disease (CD) with obefazimod, disclosing the enrolment of the first patient. This phase IIb study (NCT06456593) named ENHANCE-CD is a multicentre, double-blind, randomized, placebo-controlled trial, with a design comparable to the com

October 4, 2024 October 4, 2024 1 EN

Bruno Bulic

Bruno Bulic

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Dropping Coverage

On the shelves now: Consumer weekly #42

Abivax: Obefazimod in Crohn's disease clinical development

Abivax positive long-term Ph. II data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe